Merck & Co., Inc. Investment Insights in Q4 2023

During the fourth quarter, the Supplemental Annuity Collective Trust of New Jersey significantly increased its investment in Merck & Co., Inc., raising its holdings by 46.8%, according to a filing with the Securities and Exchange Commission. This adjustment resulted in ownership of 49,900 shares, with Merck stocks representing 1.4% of the trust’s portfolio, making it their tenth-largest holding valued at $5,252,000.

Several other major institutional investors also adjusted their stakes in Merck. DLD Asset Management LP increased its shares by 30.1% during the third quarter, while Invesco Ltd. expanded its position by 16.6%. Ameriprise Financial Inc. boosted its holdings by 20.7%, and Vanguard Group Inc. saw a smaller increment of 0.9% during the fourth quarter. Van ECK Associates Corp expanded its shares by 61.6%. Collectively, institutional investors hold 76.07% of Merck’s total outstanding stock.

In other developments, Merck & Co., Inc.’s CEO Robert M. Davis and EVP Richard R. Deluca recently engaged in stock transactions. Davis sold 47,434 shares, impacting his holdings by a 9.66% reduction, while Deluca sold 37,685 shares, marking a 19.05% decrease in his shares. These transactions are documented in filings with the SEC.

Analysts have offered varied assessments on Merck. Zacks Research recently upgraded Merck's rating to "hold," and the Royal Bank of Canada reiterated an "outperform" rating, setting a $142 price target. Citigroup raised its target price from $120 to $125, maintaining a "neutral" stance. According to MarketBeat, Merck carries an average rating of "Moderate Buy" from analysts.

Financially, Merck reported earnings of $2.04 per share for the last quarter, slightly above the analysts' forecast of $2.01. The firm's revenue improved by 5% year-over-year to $16.40 billion. Merck’s profitability metrics remain strong, with a net margin of 28.08% and a return on equity of 44.57%. The insurer announced a quarterly dividend of $0.85 per share, maintaining a dividend yield of 3.0% with a payout ratio of 46.70%.

Merck & Co, Inc. operates globally as a biopharmaceutical leader, noted for its innovations in oncology, vaccines, and therapies for infectious and chronic conditions. Notable products include the cancer therapy Keytruda and the vaccine Gardasil. Through Merck Animal Health, the company also markets an array of animal vaccines and treatments. Founded in the late 19th century, Merck remains a significant player in the pharmaceutical landscape.

This article utilizes data sourced from MarketBeat to provide up-to-date and precise industry insights.